Autore	Liu Wanli
Edizione	[1st ed. 2025.]
Pubbl/distr/stampa	Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2025
Descrizione fisica	1 online resource (126 pages)
Disciplina	616.994
Altri autori (Persone)	ZengYingyue
Soggetto topico	Cancer - Treatment Cancer Immunotherapy Immunology Tumors - Immunological aspects Cancer Therapy Cancer Biology Tumour Immunology
ISBN	9789819610273 9819610273
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Nota di contenuto	-- Chapter 1_ Introduction. -- Chapter 2_ BCR Composition and Structure. -- Chapter 3_ Early Events in Antigen-Induced B Cell Activation. -- Chapter 4_ The Mechanism of IgG-BCR Mediated Memory Antibody Response. -- Chapter 5_ B Cell Mechanosensing. -- Chapter 6_ Techniques for Antigen-Induced B Cell Activation Imaging. -- Chapter 7_ Techniques to Measure B Cell Mechanosensing and BCR Conformational Changes. -- Chapter 8_ B Cell and Autoimmune Diseases. -- Chapter 9_ Tumor Immunity and Monoclonal Antibody Therapies.
Record Nr.	UNINA-9910983487403321

Autore	Rezaei Nima
Edizione	[1st ed. 2024.]
Pubbl/distr/stampa	Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024
Descrizione fisica	1 online resource (436 pages)
Disciplina	571.978 616.994
Collana	Interdisciplinary Cancer Research
Soggetto topico	Cancer Cancer - Treatment Cancer - Genetic aspects Oncology Tumors - Immunological aspects Immunotherapy Cancer Biology Cancer Therapy Cancer Genetics and Genomics Tumour Immunology
ISBN	9783031658082 9783031658075
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Nota di contenuto	Role of miRNAs in Triple-Negative Breast Cancer: Diagnosis, Prognosis, and Treatment -- Approaches to Breast Cancer Immunology and Immunotherapy -- Molecular Genetics of Breast Cancer: From Mechanistic Insights to the Therapeutic Approaches -- Interleukins in the Development and Progression of Breast Cancer -- Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer -- The Prognostic Impact of Tumor-Infiltrated Lymphocytes (TILs) in Breast Cancer -- From Genes to Recovery: Precision Medicine and Its Influence on Multidrug Resistant Breast Cancer -- Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment -- Targeting Myeloid Determinants of Breast Cancer -- siRNA Loaded in Drug Delivery Nanosystems as a Strategy for Breast Cancer Treatment -- Nucleic Acid and Drug Dual Agent Nanoplatforms for Breast Cancer -- Oncolytic Virotherapy Against Breast Cancer -- Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development.
Record Nr.	UNINA-9910874677603321

Pubbl/distr/stampa	Amsterdam ; ; Boston, : Academic Press, c2007
Descrizione fisica	1 online resource (429 p.)
Disciplina	616.99/4061
Altri autori (Persone)	PrendergastGeorge C JaffeeElizabeth M
Soggetto topico	Cancer - Immunotherapy Antineoplastic agents - Therapeutic use Tumors - Immunological aspects
Soggetto genere / forma	Electronic books.
ISBN	1281020451 9786611020453 0080521851
Formato	Materiale a stampa
Livello bibliografico	Monografia
Lingua di pubblicazione	eng
Nota di contenuto	Front cover; Cancer Immunotherapy: Immune Suppression and Tumor Growth; Copyright page; Table of contents; Contributors; PART I: PRINCIPLES OF CANCER IMMUNOBIOLOGY; CHAPTER 1: Introduction; I. OVERVIEW; II. HISTORICAL BACKGROUND; III. LOOKING AHEAD: MARRYING CHEMOTHERAPY AND IMMUNOTHERAPY; IV. PARTS OF THE BOOK; References; Further Reading; CHAPTER 2: Cancer Immunoediting: From Immune Surveillance to Immune Escape; I. INTRODUCTION; II. CANCER IMMUNE SURVEILLANCE; III. CANCER IMMUNOEDITING; IV. CONCLUDING REMARKS; References CHAPTER 3: Immunosurveillance: Innate and Adaptive Antitumor ImmunityI. INTRODUCTION; II. INNATE ANTITUMOR RESPONSES; III. INNATE IMMUNE CELLS; IV. ADAPTIVE ANTITUMOR RESPONSES; V. THE INTERPLAY OF INNATE AND ADAPTIVE ANTITUMOR IMMUNITY; VI. CONCLUSION; References; CHAPTER 4: Cytokine Regulation of Immune Tolerance to Tumors; I. INTRODUCTION; II. CYTOKINE REGULATION OF IMMUNE TOLERANCE TO TUMORS; III. SUMMARY AND FUTURE PERSPECTIVES; References; CHAPTER 5: Immunological Sculpting:Natural Killer Cell Receptorsand Ligands; I. INTRODUCTION; II. ACTIVATING HUMAN NK RECEPTORS III. INHIBITORY NK RECEPTORSIV. THE LY49 RECEPTOR FAMILY; V. IMMUNOTHERAPY APPROACHES; VI. CONCLUSION; References; Further Reading; CHAPTER 6: Immune Escape:Immunosuppressive Networks; I. INTRODUCTION; II. IMBALANCE BETWEEN MATURE DCs AND IMMATURE DCs; III. IMBALANCE BETWEEN STIMULATORY AND INHIBITORY B7 FAMILY MOLECULES; IV. IMBALANCE BETWEEN REGULATORY T CELLS AND CONVENTIONAL T CELLS; V. CONCLUDING REMARKS; References; PART II: CANCER THERAPEUTICS; CHAPTER 7: Cytotoxic Chemotherapy inClinical Treatment of Cancer; I. INTRODUCTION; II. DNA-DAMAGING AGENTS; III. ANTIMETABOLITES IV. ANTIMITOTICS V. CHEMOTHERAPY REGIMENS; References; Useful Web Sites; CHAPTER 8: Targeted Therapeutics in Cancer Treatment; I. INTRODUCTION; II. CELL CYCLE; III. THE MAPK FAMILY; IV. CHALLENGES IN THE CLINICAL DEVELOPMENT OF SIGNAL TRANSDUCTION INHIBITORS; References; CHAPTER 9: Concepts in Pharmacology and Toxicology; I. INTRODUCTION; II. CONCEPTS IN PHARMACOKINETICS; III. CONCEPTS IN TOXICOLOGY; IV. CLINICAL CONCERNS FOR PHARMACOLOGY AND SAFETY; V. CONCLUSION; References; Further Reading; CHAPTER 10: Cancer Immunotherapy:Challenges and Opportunities; I. INTRODUCTION II. PREREQUISITES FOR EFFECTIVE CANCER IMMUNOTHERAPY: IDENTIFYING TUMOR ANTIGENS III. ADOPTIVE ("PASSIVE") IMMUNOTHERAPY; IV. ACTIVE-SPECIFIC IMMUNOTHERAPY: VACCINES; V. CANCER-INDUCED IMMUNOSUPPRESSION IMPINGES ON IMMUNOTHERAPY; VI. CANCER IMMUNOTHERAPY IN MICE VERSUS HUMANS; VII. IMMUNOTHERAPY AND CANCER STEM CELLS; VIII. AUTOIMMUNITY RESULTING FROM CANCER IMMUNOTHERAPY; IX. CONCLUSION AND FUTURE CONSIDERATIONS; References; CHAPTER 11: Cancer Vaccines; I. INTRODUCTION; II. TUMOR ANTIGENS; III. SPONTANEOUS IMMUNITY TO CANCER; IV. TOLERAGENIC PRESSURE ON IMMUNITY TO CANCER V. IMMUNE RESPONSES TO CONVENTIONAL VACCINES
Record Nr.	UNINA-9910458644103321